CMRX waiting for news Now we just need some news to get dropped. Some positive ones, and we are ready to do.
2.0644USD
172.167MUSD
33.824MUSD
79.291M
About Chimerix, Inc.
Sector
CEO
Michael T. Andriole
Headquarters
Durham
Website
Employees (FY)
89
Founded
2000
ISIN
US16934W1062
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
target 2.90 ( 1 to 5 months )Good Technical ( Nice Breakout ) and Good Fundamental ( Good Result ) , So Target 2.90 , Duration 1 to 5 months.
Chimerix Awarded BARDA Contract for TEMBEXACMRX: Chimerix, Inc.
2022-08-29 10:45:00 Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
Chimerix Announces Positive Topline Results for ONC201 in RecurrCMRX: Chimerix, Inc.
2021-11-04 07:00:00
Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma
CMRX 2/7/2020Analysis-
Daily chart- After long downtrend, price has been in sideways market between 1.24-3.38 for 638 days. After making a move to resistance on July2020, price fell and found support from 200 MA then working itself back to resistance and finally breaking out. After breakout of 40%, price pulled
CMRX descending wedge formedsimple wedge formed in order to add onto my long term hold once we hopefully bounce off of the 3.26 fib level
CMRX daily 160% gains setup(STOCKS)before we kick start the update. your upvotes/subs are appreciated.
Why get subbed to to me on Tradingview?
-15+ years real live trading experience
-TOP Author on TradingView
-professional chart break downs
-key levels
-no junk on my charts
-frequent updates
-covering FX/crypto/US stocks
-24/7
$CMRX Chimerix Inc Moving big pore market - Covid-19DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Company’s initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patie
CMRX COVID planI am currently long term bullish on CMRX. I see much upside for them once they can get FDA approval. I have been adding shares at the supports I have listed.
NASDAQ:CMRX
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
